{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-23-000015","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.351908+00:00","generated_at":"2026-06-17T05:50:23.718467+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense","bullets":["Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.","Q1 2023 adjusted diluted EPS guidance lowered to $2.31-$2.41 from $2.39-$2.49.","Full-year 2023 adjusted diluted EPS guidance lowered to $10.62-$11.02 from $10.70-$11.10.","Company does not forecast future IPR&D and milestones expense; guidance excludes any beyond Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-23-000015","json":"https://secwatch.observer/filing/0001551152-23-000015.json","markdown":"https://secwatch.observer/filing/0001551152-23-000015.md","text":"https://secwatch.observer/filing/0001551152-23-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/0001551152-23-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/abbv-20230405.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:50:23.718467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}